Antares Pharma (ATRS) Reports In-Line Q2 EPS

August 9, 2016 7:50 AM EDT
Get Alerts ATRS Hot Sheet
Trade ATRS Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Antares Pharma (NASDAQ: ATRS) reported Q2 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $11 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment